GH-Axis & Endocrine SignalingCJC-1295 (No DAC)
A synthetic analogue of growth hormone-releasing hormone (GHRH 1-29) engineered without a Drug Affinity Complex, giving it a short circulating window compared to its DAC-conjugated counterpart.
This is a lab-made copy of the signal your body naturally sends to release growth hormone, minus the chemical tag that would make it linger for days. Researchers use it to study a quick, natural-feeling pulse of GH release rather than a slow drip.
Modified GHRH(1-29) analogue without Drug Affinity Complex (DAC)
Short circulating half-life compared to DAC-conjugated GHRH analogues
Frequently studied in combination with ghrelin-receptor agonists like Ipamorelin
Supports research into pulsatile, physiologic-pattern GH release
Mechanism
Scientific Mechanism
CJC-1295 (No DAC) is a truncated GHRH(1-29) analogue that binds GHRH receptors on pituitary somatotrophs, activating adenylate cyclase and cAMP-dependent signaling that drives GH synthesis and release. Because it lacks the Drug Affinity Complex used in long-acting GHRH analogues, it does not bind serum albumin for extended circulation, so it clears the bloodstream within roughly 30 minutes. Research groups value this short window specifically because it is thought to preserve a more physiologic, pulsatile GH-release pattern when studied alone or in combination with ghrelin-receptor agonists.
Mechanism Detail
How It Works
CJC-1295 (No DAC) is studied through direct GHRH-receptor engagement in the pituitary:
ghrh: Binds GHRH receptors on somatotroph cells in the anterior pituitary
release: Triggers cAMP-mediated signaling that stimulates synthesis and release of growth hormone
pulsatility: Because it lacks DAC, it clears quickly, which research suggests supports a pulsatile release pattern rather than sustained elevation
synergy: Frequently studied alongside ghrelin-receptor agonists (GHRPs), which act on a separate receptor and are reported to produce an additive GH-release effect in combination
Research Evidence
What the Research Shows
Growth Hormone
• Research shows dose-dependent stimulation of growth hormone release from the pituitary in both animal and human studies
• Studies demonstrate a short-acting pharmacokinetic profile consistent with the exclusion of the DAC moiety
• Evidence suggests the resulting GH release pattern more closely mirrors the body's natural pulsatile secretion than long-acting GHRH analogues
Research Dosing
Dosing & Administration Reference
THIS IS FOR EDUCATIONAL PURPOSES ONLY. Not a protocol for human or animal dosing. Always follow your institution's research and healthcare provider's guidance.
Starting Dose
0.1-0.2mg per administration (in research studies)
Titration
Research protocols generally hold a fixed dose rather than titrate, given the short half-life
Maintenance
0.1-0.2mg, 1-3 times daily depending on study design
Study Duration
8-16 weeks in most research protocols
Reconstitution Calculator
Reconstitution math for research reference only. Not dosing guidance.
Reconstitution ReferenceDiluent: Bacteriostatic water (0.9% benzyl alcohol)
Example Vial: 10mg peptide
BAC Water: 2.0mL
Concentration: 5.0mg per 1mL
Storage & Handling
Stability Protocol
Lyophilized powder: store at -20°C with desiccant, protected from light. Reconstituted solution: refrigerate at 2-8°C, discard after 28-30 days or if cloudiness/particulate appears.
References
Research Sources
Related
Frequently Researched Alongside
Research Use Only: Intended for in-vitro laboratory research only. Not for human or animal consumption. This page provides educational and research-context information only — it does not constitute dosing, administration, or medical advice.